Reacción a "Both the drug orforglipron and a probiotic supplement help patients with obesity maintain their weight loss, according to two independent clinical trials "

These two trials are significant because they address one of the most challenging aspects of obesity treatment: not so much losing weight, but maintaining the weight lost. The orforglipron trial is a phase 3b, randomised, double-blind, placebo-controlled study in people who had previously lost weight with tirzepatide or semaglutide. Its results support the idea that switching from an injectable treatment to an oral GLP-1 receptor agonist may help preserve a substantial portion of the weight loss achieved, which could have important practical implications for treatment adherence, acceptability and scalability. The trial with pasteurised Akkermansia muciniphila is smaller, but also randomised and double-blind, and suggests that targeting the microbiota–metabolism axis could modestly help reduce weight regain following a low-calorie diet, with interesting signals regarding insulin sensitivity and possible differences depending on baseline Akkermansia abundance.

That said, both studies should be interpreted with caution. In the case of orforglipron, the comparator was placebo rather than continued injectable treatment, so it is not possible to conclude whether switching to the oral route is equivalent to continuing with semaglutide or tirzepatide. Furthermore, the follow-up period was one year and the population was from the United States, with limited diversity. In the case of Akkermansia, the sample size was small, the follow-up period was 24 weeks after weight loss, and the effects, whilst promising, are modest and require confirmation in longer and more diverse studies. Taken together, the two studies reinforce an important idea: obesity must be understood as a chronic, biologically defended condition, where maintenance requires sustained strategies. They also point towards a more combined and personalised future, where drugs, nutrition, microbiota, behaviour and individual patient characteristics are integrated to improve the durability of results.